BeOne Medicines Ltd. SEC Filings

BeOne Medicines Ltd. (ONC) Form 144 notifies a proposed sale of 122 American Depositary Shares (ADS) to be executed through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ with an aggregate market value of $39,864.72. The filing reports the ADS were acquired on 08/31/2025 by restricted stock vesting under a registered plan and that payment/consideration is noted as Not Applicable.

The filing lists prior sales by the same person, Titus Benjamin Ball, of 134 ADS and 137 ADS on 06/11/2025 with gross proceeds of $34,620.05 and $26,021.78, respectively. Certain filer/contact fields and the notice date/signature are not populated in the provided content.

BeOne Medicines Ltd. furnished an 8-K to note that its STAR Interim Report for the six months ended June 30, 2025 was prepared under PRC GAAP (China Accounting Standards) as required by PRC Securities Laws. The filing states a supplemental exhibit (Exhibit 99.1) provides the company’s research and development expenses allocated by key products and other R&D projects prepared in accordance with U.S. GAAP, plus a summary of material differences between PRC GAAP and U.S. GAAP. The STAR Interim Report is available publicly in Chinese on the Shanghai Stock Exchange website, but that report and the SSE website content are explicitly not being filed with or incorporated into the company’s U.S. SEC filings. Information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, and therefore is not subject to Section 18 liabilities.

BeOne Medicines entered a royalty sale with Royalty Pharma providing an upfront payment of $885 million at closing in exchange for a significant portion of tiered mid-single-digit royalties on Imdelltra (tarlatamab) sales outside China. The Seller retains other economic rights under the Amgen Collaboration Agreement and may, through August 25, 2026, exercise a put option to sell an additional portion of royalties for up to $65 million. The Seller will share in royalties on annual Imdelltra ex-China net revenue above $1.5 billion. All Amgen royalty payments to the Seller are to be deposited into an escrow account, and the agreement includes customary representations, warranties, covenants and indemnities. BeOne expects the upfront payment to become a material direct financial obligation at closing. The filing also discloses forward-looking statements and enumerates clinical, regulatory, intellectual property, funding and third-party risks.

Wu Xiaobin, President and COO of BeOne Medicines Ltd. (ONC), reported multiple transactions on 08/13/2025 and 08/14/2025 involving the company’s American Depositary Shares (ADS) and stock options. The filing states each ADS represents 13 ordinary shares. The reporting person sold multiple blocks of ADS under a Rule 10b5-1 trading plan adopted May 13, 2024 (amended May 14, 2025), with reported weighted-average sale prices ranging roughly from $300.00 to $308.12 across the transactions. The filing also shows a series of option grants/rights: 296,049, 352,105, 399,828, and 119,340 ordinary-share equivalents (various exercise prices and vesting schedules), and indicates direct and indirect ownership entries including shares held by the reporting person’s wife.

BeOne Medicines reporting person Henry Lee (SVP, General Counsel and Director) disclosed multiple ADS and option transactions on 08/13/2025. The filing shows several sales of American Depositary Shares under a Rule 10b5-1 plan adopted May 14, 2025, including disposals at weighted-average prices of $300 and $301.00 per ADS and a separate sale at $300.1858. The report also records acquisitions of ADS at prices of $194.47 and $159.03 and net changes in ordinary shares reflecting ADS conversions (1 ADS = 13 ordinary shares). Two option grants (or holdings) remain outstanding with exercise prices of $14.96 and $12.23 covering 56,953 and 50,037 ordinary shares respectively, and vesting schedules described in the filing.

BeOne Medicines Ltd. (ONC) submitted a Form 144 proposing the sale of 89,794 ADS through Morgan Stanley Smith Barney LLC on NASDAQ, showing an aggregate market value of $25,869,651.40 and 54,564,278 ADS outstanding. The approximate sale date is 08/13/2025.

The filing states the ADS were acquired on 08/13/2025 by exercise of stock options from the issuer and paid in cash. It also lists prior common-share sales by Xiaobin Wu in June 2025: 1,363 (6/23/2025) for $354,380.00, 630 (6/17/2025) for $158,047.22, 1,543 (6/16/2025) for $409,694.43, and 1,934 (6/06/2025) for $489,590.94. The notice includes the standard representation that the filer does not possess undisclosed material adverse information.

BeOne Medicines Ltd. (ONC) filed a Form 144 disclosing a proposed sale of 10,338 ADS on NASDAQ with an aggregate market value of $2,978,377.80. The filing shows those ADS were acquired partly by an exercise of stock options (9,226 ADS, cash paid on 08/13/2025) and partly as restricted stock units (1,112 ADS on 06/05/2025). The notice lists 54,564,278 shares outstanding, and the proposed block represents a very small portion of outstanding shares.

The filing also discloses recent sales by the same seller over the past three months: 2,042 common shares sold on 07/30/2025, 06/16/2025 and 06/06/2025 for combined gross proceeds of $571,975.61. This Form 144 is a regulatory notice of intent to sell and records the means of acquisition and prior dispositions.